PMLS Virtual Series 2021 – Clinical Trials in Precision Medicine
On Demand Now Click Here
March 16, 2021
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Vice Chair, Medical Oncology, Cancer Treatment Centers of America (CTCA), Philadelphia, Chief Medical Advisor & Co-Founder, Massive Bio
Arturo Loaiza-Bonilla, MD, MSEd, FACP
Vice Chair, Medical Oncology, Cancer Treatment Centers of America (CTCA), Philadelphia, Chief Medical Advisor & Co-Founder, Massive Bio
Dr. Loaiza-Bonilla is Vice Chairman of the Department of Medical Oncology at Cancer Treatment Centers of America (CTCA) in Philadelphia, Pennsylvania. Dr. Loaiza-Bonilla is dedicated to comprehensive care for patients suffering from gastrointestinal malignancies, such as colon, esophagus, gastric, liver, pancreas, and neuroendocrine tumors. Dr. Loaiza-Bonilla earned a medical degree from the Universidad Nacional de Colombia in Bogotá, Colombia. Following medical school, he completed an Internship and Residency in Internal Medicine at Harbor Hospital Center in Baltimore, Maryland. Dr. Loaiza-Bonilla also completed a Fellowship in Hematology and Oncology at the University of Miami, Miller School of Medicine. Prior to joining CTCA, Dr. Loaiza-Bonilla was an Assistant Professor of Clinical Medicine at the Perelman School of Medicine at the University of Pennsylvania. During this time, he completed his master’s degree in medical education at the same university. Dr. Loaiza-Bonilla has been published in several medical journals and oncology publications. He is also a reviewer and counselor for several journals, special interest groups, panels and academic competitions. He has also served as principal investigator and co-investigator for many large oncology clinical trials. Dr. Loaiza-Bonilla has been a member and held leadership positions for several medical organizations. These include the Pennsylvania Society of Oncology and Hematology, the American Society of Hematology, the American Society of Clinical Oncology, and the American Association of Cancer Research.
Colin Enderlein, MS
Senior Associate, DeciBio Consulting
Colin Enderlein, MS
Senior Associate, DeciBio Consulting
Colin Enderlein has been active in precision medicine innovation and CDx commercialization at multiple phases of the R&D value chain in both the public and private sectors. Following the completion of his graduate work at The Karolinska Institute, Colin worked with the business development team at Seattle Children’s Research Institute to establish industry partnerships with a focus on curing childhood diseases. From here, Colin joined the business development team at NanoString, where activities focused on CDx partnering and execution, and technology due diligence. He is currently a Project Leader with DeciBio Consulting, where he specializes in research related to I/O therapies and their associated biomarkers, spanning both the pharmaceutical and genomic tools markets.
Sundarkia Hill, MS
Director, Precision Enrollment Network, IQVIA
Sundarkia Hill, MS
Director, Precision Enrollment Network, IQVIA
Sundarkia Hill serves as Director of the IQVIA Precision Enrollment Network, the just-in-time start up service for clinical trials. In this role, she is responsible for developing patient recruitment support strategies for complex oncology and rare disease trials, and oversees the completion of site start-up activities within 21 days of the identification of an eligible patient.
Ms. Hill resides in Atlanta, GA, by way of Leland, NC. She studied Applied Science (concentration in biomedical engineering) as an undergraduate at the University of North Carolina at Chapel Hill. She continued her graduate studies in Biology (concentration in molecular genetics and biochemistry) while working as a research study coordinator for a urology practice. Passionate about a career in clinical research, Ms. Hill joined Quintiles, now IQVIA, as a CRA in 2006.
Ms. Hill has broad experience across the clinical trial landscape, including site-level and CRO-level management of project duties. Much of her experience involved identifying the needs of internal and external customers, proposing solutions, and meeting deliverables. Ms. Hill has a successful track record of generating and managing key relationships in support of projects, as well as managing high-performing teams to execute project tasks. Her therapeutic experience includes Oncology, Urology, Infectious Diseases, Cardiology, Gastroenterology, Rheumatology, and Nephrology.
Selin Kurnaz, PhD
Chief Executive Officer and Co-Founder, Massive Bio
Selin Kurnaz, PhD
Chief Executive Officer and Co-Founder, Massive Bio
Dr. Selin Kurnaz is the Chief Executive Officer and Co-Founder of Massive Bio. After emigrating from Turkey and completing a PhD at the University of Michigan, receiving multiple engineering degrees, Selin spent more than a decade specializing in delivering revenue enhancement, margin optimization and capital efficiency improvements for Healthcare and Life Science companies. Her startup, Massive Bio, brings the latest knowledge in cancer care to patients treated at community practices in the US and worldwide. Selin has written and spoken extensively about life sciences in tech and how to deliver information in creative ways. Massive Bio is an alumni of eLab and Philips Healthworks Precision Cancer Care start-up acceleration programs.
Kamal S. Saini, MD
Executive Medical Director, Oncology, Covance Clinical Development Services
Kamal S. Saini, MD
Executive Medical Director, Oncology, Covance Clinical Development Services
Kamal S. Saini, MD, is Executive Medical Director, Oncology, for Covance Clinical Development Services, based in Brussels, Belgium. Kamal is a board-certified medical oncologist, with an active license to practice in the UK. He contributes to the scientific strategic leadership within the oncology therapeutic area at Covance, provides clinical and medical expertise to project teams, supports clinical trials as medical monitor, line manages a team of oncology physicians, and is the consultant Chief Medical Officer of a biotech company. Kamal has more than 15 years of experience in clinical research and development. He previously served as Associate Scientific Director for an academic research organization and as Medical Advisor, Institute Jules Bordet, Brussels. He is the author or co-author of several peer-reviewed journal articles.
Craig Lipset, MPH
Advisor & Founder, Clinical Innovation Partners
Craig Lipset, MPH
Advisor and Founder, Clinical Innovation Partners
Craig Lipset is the founder of Clinical Innovation Partners, providing advisory and board leadership with pharma, tech and venture capital to bring vision and driving action at the intersection of research, digital solutions, and patient engagement. Craig was the Head of Clinical Innovation and Venture Partner at Pfizer, on the founding Operations Committee for TransCelerate Biopharma, and on the founding management teams for two successful startup ventures.
Craig is Adjunct Assistant Professor in Health Informatics at Rutgers University, and Adjunct Instructor in the Center for Health + Technology at University of Rochester. He serves on the Board of Directors for the Foundation for Sarcoidosis Research and the MedStar Health Research Institute, as well as on the Editorial Board for Therapeutic Innovation & Regulatory Science.
Craig has been listed among the PharmaVOICE most inspiring people in the life sciences (Red Jacket hall-of-fame), Pharmaceutical Executive’s Emerging Leaders, CenterWatch Top 20 Innovators in Clinical Trials, and the AlleyWatch Who’s Who in eHealth.
Isaac R. Rodriguez-Chavez, PhD, MHS, MS
Senior Vice President, Scientific and Clinical Affairs, Global Center of Excellence for Decentralized Clinical Trials, PRA Health Sciences
Isaac R. Rodriguez-Chavez, PhD, MHS, MS
Senior Vice President, Scientific and Clinical Affairs, Global Center of Excellence for Decentralized Clinical Trials, PRA Health Sciences
Dr. Isaac R. Rodriguez-Chavez is a biomedical leader with expertise in Infectious Diseases, Viral Immunology, Viral Oncology, and Vaccinology. Currently, he is a Senior Vice President for Scientific & Clinical Affairs, leading the Strategy of the Global Center of Excellence for Decentralized Clinical Trials, PRA Health Sciences. Past positions in the last 32 years include: FDA, CDER Officer for Clinical Research Methodology, Regulatory Compliance and Policy Development modernizing clinical research through Decentralized Clinical Trials enabled by Digital Health Technologies; CEO/Founder, 4Biosolutions Biomedical Consulting Firm; Vice President, Research, Texas Biomedical Research Institute; Director of HIV Clinical Research Programs, NIH; Senior Clinical Scientist, Schering Plough Corp.; Scientist, Columbia University; Scientist, Polar Biotechnology Company and Venezuelan Institute for Scientific Research (IVIC). He has a PhD in Virology and Immunology; a MS in Microbiology; a MHS in Clinical Research; and a B.S. in Biology. LinkedIn: https://www.linkedin.com/in/isaacrc/